Based on the supplied data, RGC shows no consistently disclosed revenue line, with operating losses reaching $6.4M in 2026Q4 against SG&A of $5.1M, suggesting a structurally negative operating model without a visible path to breakeven.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Reported revenue is absent across the ten-quarter period while operating losses widened to $6.4M in 2026Q4, driven by SG&A of $5.1M that dwarfs R&D of $883.6K, so margin trends cannot be meaningfully established.
AI models forecast a 15.0% increase in RGC stock price to $17.16 in 2026, with a 29.32% potential short-term gain based on correlation patterns.
Deep fundamental analysis and smart money sentiment suggest potential investment opportunities in Regencell Bioscience's financial health.
Regencell Bioscience's technology and sector exposure may present growth opportunities, as indicated by expert analysis and market trends.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 28, 2026 | -$0.01 vs — | — vs — |
Q3 2026 Jun 15, 2026 | -$0.01 vs — | — vs — |
Q4 2025 Nov 18, 2025 | -$0.00 vs — | — vs — |
Q3 2025 Jun 26, 2025 | -$0.14 vs — | — vs — |
Regencell Bioscience (NASDAQ: RGC - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.01) earnings per share (EPS) for the quarter, FiscalAI reports. Regencell Bioscience Price Performance NASDAQ: RGC opened at $7.11 on Thursday. The stock has a 50-day simple moving average of $5.92 and a two-hundred day simple moving average of
ROANOKE, Va., Sept. 28, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of RGC Resources, Inc. (Nasdaq: RGCO) declared a quarterly dividend of $0.2175 per share on the Company's common stock.
RGC Resources is a micro-cap natural gas utility with limited growth prospects and a small, stable service area. RGCO's earnings growth remains sluggish, with FY 2026 guidance implying just 1.2% year-over-year EPS growth and a PE of 15.7. The company offers a 4.04% forward dividend yield, supported by an 82-year dividend history and consistent annual payout increases.
Benchmark RGC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Regencell Bioscience Holdings Limited (RGC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.27 | $2.61B | -222.36 | — | — | -128.52% | — | |
| $4.16 | $1.44B | -10.77 | 698.96% | -67.38% | -49.11% | — | |
| $12.37 | $154.54M | -52.77 | 14.52% | -7.12% | -74.71% | — | |
| $3.10 | $222.34M | -80.94 | -31.8% | -5.14% | -1.53% | 19.42% | |
| $277.62 | $7.74B | -23.85 | -100% | — | -34.15% | — | |
| $44.61 | $2.86B | 28.34 | 15.24% | 10.2% | 5.22% | 0.25% |
Regencell Bioscience Holdings Limited (RGC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when RGC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Regencell Bioscience Holdings Limited (RGC) stock FAQ — growth, dividends, profitability & financials explained
No. Regencell Bioscience Holdings Limited (RGC) reported a net loss of $11.7M in fiscal year 2026.
Regencell Bioscience Holdings Limited (RGC) had a return on equity (ROE) of -128.5% in fiscal year 2026. A negative ROE means the company lost money over the period.
Regencell Bioscience Holdings Limited (RGC) had negative free cash flow of $7.7M in fiscal year 2026.
